That's a long bow to draw. I doubt you'd have to question the clinical research. The trials and results would have been independently audited and assessed.
I suspect it's more likely that there has been fiddling with the invoicing/accounts to boost the chance of a performance bonus, or perhaps options are coming up for expiry and will lapse given the languishing share price.
trading halt, page-149
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
-0.001(20.0%) |
Mkt cap ! $7.923M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $5.333K | 2.666M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 31084472 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 35403846 | 21 |
View Market Depth
| Last trade - 14.22pm 10/10/2024 (20 minute delay) ? |
| AVE (ASX) Chart |